References
- Rehman S , WenX , CaseyMJet al. Effect of different tacrolimus levels on early outcomes after kidney transplantation . Ann. Transplant.19 , 68 – 75 ( 2014 ).
- Israni AK , RiadSM , LeducRet al. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics . Transpl. Int.26 , 982 – 989 ( 2013 ).
- de Jonge H , de LoorH , VerbekeKet al. Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism . Pharmacogenomics14 , 1467 – 1480 ( 2013 ).
- de Jonge H , de LoorH , VerbekeKet al. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients . Clin. Pharmacol. Ther.92 , 366 – 375 ( 2012 ).
- Li CJ , LiL , LinLet al. Impact of the CYP3A5, CYP3A4, COMT, IL–10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients . PLoS ONE9 ( 1 ), e86206 ( 2014 ).
- Murray B , HawesE , LeeRAet al. Genes and beans: pharmacogenomics of renal transplant . Pharmacogenomics14 , 783 – 798 ( 2013 ).
- Oneda B , CrettolS , Jaquenoud SirotEet al. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test . Pharmacogenet. Genomics19 , 877 – 883 ( 2009 ).
- Zhang JJ , ZhangH , DingXLet al. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers . Eur. J. Clin. Pharmacol.69 , 807 – 812 ( 2013 ).
- de Jonge H , MetalidisC , NaesensMet al. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients . Pharmacogenomics12 , 1281 – 1291 ( 2011 ).
- Elens L , HesselinkDA , BouamarRet al. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients . Ther. Drug Monit.36 , 71 – 79 ( 2014 ).
- Naik P , MadhavarapuM , MayurPet al. Pharmacokinetics of tacrolimus in adult renal transplant recipients . Drug Metabol. Drug Interact.27 , 151 – 155 ( 2012 ).
- Cherala G , MunarMY , NaherAet al. Tacrolimus pharmacokinetics in Hispanic children after kidney transplantation . Transplant. Proc.43 , 3708 – 3712 ( 2011 ).
- Wallin JE , BergstrandM , WilczekHEet al. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance . Ther. Drug Monit.33 , 663 – 672 ( 2011 ).
- Gijsen VM , van SchaikRH , ElensLet al. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients . Pharmacogenomics14 , 1027 – 1036 ( 2013 ).
- Jalil MH , HawwaAF , McKiernanPJet al. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients . Br. J. Clin. Pharmacol.77 , 130 – 140 ( 2014 ).